Key Points
-
Vascular endothelial growth factor (VEGF) has been implicated in the aetiology and treatment of various neurological diseases
-
VEGF exerts effects on multiple cell types in the nervous system, including endothelial cells, neurons, astrocytes, microglia, oligodendrocytes and Schwann cells
-
VEGF protects neurons and fosters neurogenesis, and reduced VEGF levels contribute to neurodegenerative disorders
-
VEGF can improve brain perfusion, partly by promoting angiogenesis, but pathological VEGF levels induce blood–brain barrier breakdown and vessel leakage
-
Preclinical studies indicate that VEGF administration is beneficial in neurodegenerative diseases, peripheral neuropathies and epilepsy
-
VEGF inhibition is approved as a treatment for neovascular ocular diseases, and might be beneficial in other neurological disorders involving BBB breakdown or excessive angiogenesis
Abstract
Brain function critically relies on blood vessels to supply oxygen and nutrients, to establish a barrier for neurotoxic substances, and to clear waste products. The archetypal vascular endothelial growth factor, VEGF, arose in evolution as a signal affecting neural cells, but was later co-opted by blood vessels to regulate vascular function. Consequently, VEGF represents an attractive target to modulate brain function at the neurovascular interface. On the one hand, VEGF is neuroprotective, through direct effects on neural cells and their progenitors and indirect effects on brain perfusion. In accordance, preclinical studies show beneficial effects of VEGF administration in neurodegenerative diseases, peripheral neuropathies and epilepsy. On the other hand, pathologically elevated VEGF levels enhance vessel permeability and leakage, and disrupt blood–brain barrier integrity, as in demyelinating diseases, for which blockade of VEGF may be beneficial. Here, we summarize current knowledge on the role and therapeutic potential of VEGF in neurological diseases.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Koch, S. & Claesson-Welsh, L. Signal transduction by vascular endothelial growth factor receptors. Cold Spring Harb. Perspect. Med. 2, a006502 (2012).
Ruiz de Almodovar, C., Lambrechts, D., Mazzone, M. & Carmeliet, P. Role and therapeutic potential of VEGF in the nervous system. Physiol. Rev. 89, 607–648 (2009).
London, N. R. & Gurgel, R. K. The role of vascular endothelial growth factor and vascular stability in diseases of the ear. Laryngoscope 124, E340–E346 (2014).
Dewerchin, M. & Carmeliet, P. Placental growth factor in cancer. Expert Opin. Ther. Targets 18, 1339–1354 (2014).
Chinot, O. L. & Reardon, D. A. The future of antiangiogenic treatment in glioblastoma. Curr. Opin. Neurol. 27, 675–682 (2014).
Carmeliet, P. & Jain, R. K. Molecular mechanisms and clinical applications of angiogenesis. Nature 473, 298–307 (2011).
Moens, S., Goveia, J., Stapor, P. C., Cantelmo, A. R. & Carmeliet, P. The multifaceted activity of VEGF in angiogenesis — implications for therapy responses. Cytokine Growth Factor Rev. 25, 473–482 (2014).
Ferrara, N. & Adamis, A. P. Ten years of anti-vascular endothelial growth factor therapy. Nat. Rev. Drug Discov. 15, 385–403 (2016).
Dvorak, H. F., Brown, L. F., Detmar, M. & Dvorak, A. M. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am. J. Pathol. 146, 1029–1039 (1995).
Licht, T. & Keshet, E. Delineating multiple functions of VEGF-A in the adult brain. Cell. Mol. Life Sci. 70, 1727–1737 (2013).
Krishnapati, L. S. & Ghaskadbi, S. Identification and characterization of VEGF and FGF from Hydra. Int. J. Dev. Biol. 57, 897–906 (2013).
Mackenzie, F. & Ruhrberg, C. Diverse roles for VEGF-A in the nervous system. Development 139, 1371–1380 (2012).
Quaegebeur, A., Lange, C. & Carmeliet, P. The neurovascular link in health and disease: molecular mechanisms and therapeutic implications. Neuron 71, 406–424 (2011).
Hogan, K. A., Ambler, C. A., Chapman, D. L. & Bautch, V. L. The neural tube patterns vessels developmentally using the VEGF signaling pathway. Development 131, 1503–1513 (2004).
James, J. M., Gewolb, C. & Bautch, V. L. Neurovascular development uses VEGF-A signaling to regulate blood vessel ingression into the neural tube. Development 136, 833–841 (2009).
Haigh, J. J. et al. Cortical and retinal defects caused by dosage-dependent reductions in VEGF-A paracrine signaling. Dev. Biol. 262, 225–241 (2003).
Raab, S. et al. Impaired brain angiogenesis and neuronal apoptosis induced by conditional homozygous inactivation of vascular endothelial growth factor. Thromb. Haemost. 91, 595–605 (2004).
Licht, T., Dor-Wollman, T., Ben-Zvi, A., Rothe, G. & Keshet, E. Vessel maturation schedule determines vulnerability to neuronal injuries of prematurity. J. Clin. Invest. 125, 1319–1328 (2015).
Clayton, J. A., Chalothorn, D. & Faber, J. E. Vascular endothelial growth factor-A specifies formation of native collaterals and regulates collateral growth in ischemia. Circ. Res. 103, 1027–1036 (2008).
Lucitti, J. L. et al. Formation of the collateral circulation is regulated by vascular endothelial growth factor-A and a disintegrin and metalloprotease family members 10 and 17. Circ. Res. 111, 1539–1550 (2012).
Ruiz de Almodovar, C. et al. Matrix-binding vascular endothelial growth factor (VEGF) isoforms guide granule cell migration in the cerebellum via VEGF receptor Flk1. J. Neurosci. 30, 15052–15066 (2010).
He, W. et al. CMT2D neuropathy is linked to the neomorphic binding activity of glycyl-tRNA synthetase. Nature 526, 710–714 (2015).
Schwarz, Q. et al. Vascular endothelial growth factor controls neuronal migration and cooperates with Sema3A to pattern distinct compartments of the facial nerve. Genes Dev. 18, 2822–2834 (2004).
Erskine, L. et al. VEGF signaling through neuropilin 1 guides commissural axon crossing at the optic chiasm. Neuron 70, 951–965 (2011).
Ruiz de Almodovar, C. et al. VEGF mediates commissural axon chemoattraction through its receptor Flk1. Neuron 70, 966–978 (2011).
Le Guelte, A., Dwyer, J. & Gavard, J. Jumping the barrier: VE-cadherin, VEGF and other angiogenic modifiers in cancer. Biol. Cell 103, 593–605 (2011).
Zhao, Z., Nelson, A. R., Betsholtz, C. & Zlokovic, B. V. Establishment and dysfunction of the blood–brain barrier. Cell 163, 1064–1078 (2015).
Robberecht, W. & Philips, T. The changing scene of amyotrophic lateral sclerosis. Nat. Rev. Neurosci. 14, 248–264 (2013).
Peters, O. M., Ghasemi, M. & Brown, R. H. Jr Emerging mechanisms of molecular pathology in ALS. J. Clin. Invest. 125, 1767–1779 (2015).
Ilieva, H., Polymenidou, M. & Cleveland, D. W. Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. J. Cell Biol. 187, 761–772 (2009).
Garbuzova-Davis, S. et al. Amyotrophic lateral sclerosis: a neurovascular disease. Brain Res. 1398, 113–125 (2011).
Oosthuyse, B. et al. Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat. Genet. 28, 131–138 (2001).
Lambrechts, D. et al. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat. Genet. 34, 383–394 (2003).
Lambrechts, D. et al. Meta-analysis of vascular endothelial growth factor variations in amyotrophic lateral sclerosis: increased susceptibility in male carriers of the −2578AA genotype. J. Med. Genet. 46, 840–846 (2009).
Storkebaum, E. et al. Impaired autonomic regulation of resistance arteries in mice with low vascular endothelial growth factor or upon vascular endothelial growth factor trap delivery. Circulation 122, 273–281 (2010).
Sasaki, S. Alterations of the blood–spinal cord barrier in sporadic amyotrophic lateral sclerosis. Neuropathology 35, 518–528 (2015).
Li, B., Xu, W., Luo, C., Gozal, D. & Liu, R. VEGF-induced activation of the PI3-K/Akt pathway reduces mutant SOD1-mediated motor neuron cell death. Brain Res. Mol. Brain Res. 111, 155–164 (2003).
Van Den Bosch, L. et al. Effects of vascular endothelial growth factor (VEGF) on motor neuron degeneration. Neurobiol. Dis. 17, 21–28 (2004).
Tolosa, L., Mir, M., Olmos, G. & Llado, J. Vascular endothelial growth factor protects motoneurons from serum deprivation-induced cell death through phosphatidylinositol 3-kinase-mediated p38 mitogen-activated protein kinase inhibition. Neuroscience 158, 1348–1355 (2009).
Tolosa, L., Mir, M., Asensio, V. J., Olmos, G. & Llado, J. Vascular endothelial growth factor protects spinal cord motoneurons against glutamate-induced excitotoxicity via phosphatidylinositol 3-kinase. J. Neurochem. 105, 1080–1090 (2008).
Bogaert, E. et al. VEGF protects motor neurons against excitotoxicity by upregulation of GluR2. Neurobiol. Aging 31, 2185–2191 (2010).
Lunn, J. S., Sakowski, S. A., Kim, B., Rosenberg, A. A. & Feldman, E. L. Vascular endothelial growth factor prevents G93A-SOD1-induced motor neuron degeneration. Dev. Neurobiol. 69, 871–884 (2009).
Brockington, A. et al. Expression of vascular endothelial growth factor and its receptors in the central nervous system in amyotrophic lateral sclerosis. J. Neuropathol. Exp. Neurol. 65, 26–36 (2006).
Poesen, K. et al. Novel role for vascular endothelial growth factor (VEGF) receptor-1 and its ligand VEGF-B in motor neuron degeneration. J. Neurosci. 28, 10451–10459 (2008).
Storkebaum, E. et al. Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. Nat. Neurosci. 8, 85–92 (2005).
Azzouz, M. et al. VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature 429, 413–417 (2004).
Wang, Y. et al. Vascular endothelial growth factor overexpression delays neurodegeneration and prolongs survival in amyotrophic lateral sclerosis mice. J. Neurosci. 27, 304–307 (2007).
Hwang, D. H. et al. Intrathecal transplantation of human neural stem cells overexpressing VEGF provide behavioral improvement, disease onset delay and survival extension in transgenic ALS mice. Gene Ther. 16, 1234–1244 (2009).
Dodge, J. C. et al. AAV4-mediated expression of IGF-1 and VEGF within cellular components of the ventricular system improves survival outcome in familial ALS mice. Mol. Ther. 18, 2075–2084 (2010).
Kliem, M. A. et al. Intramuscular administration of a VEGF zinc finger transcription factor activator (VEGF-ZFP-TF) improves functional outcomes in SOD1 rats. Amyotroph. Lateral Scler. 12, 331–339 (2011).
Krakora, D. et al. Synergistic effects of GDNF and VEGF on lifespan and disease progression in a familial ALS rat model. Mol. Ther. 21, 1602–1610 (2013).
Tovar-Y.-Romo, L. B., Zepeda, A. & Tapia, R. Vascular endothelial growth factor prevents paralysis and motoneuron death in a rat model of excitotoxic spinal cord neurodegeneration. J. Neuropathol. Exp. Neurol. 66, 913–922 (2007).
Dotti, C. G. & De Strooper, B. Alzheimer's dementia by circulation disorders: when trees hide the forest. Nat. Cell Biol. 11, 114–116 (2009).
Di Marco, L. Y. et al. Vascular dysfunction in the pathogenesis of Alzheimer's disease — a review of endothelium-mediated mechanisms and ensuing vicious circles. Neurobiol. Dis. 82, 593–606 (2015).
Raz, L., Knoefel, J. & Bhaskar, K. The neuropathology and cerebrovascular mechanisms of dementia. J. Cereb. Blood Flow Metab. 36, 172–186 (2016).
Van Cauwenberghe, C., Van Broeckhoven, C. & Sleegers, K. The genetic landscape of Alzheimer disease: clinical implications and perspectives. Genet. Med. 18, 421–430 (2016).
Jefferies, W. A. et al. Adjusting the compass: new insights into the role of angiogenesis in Alzheimer's disease. Alzheimers Res. Ther. 5, 64 (2013).
Kalaria, R. N., Akinyemi, R. & Ihara, M. Does vascular pathology contribute to Alzheimer changes? J. Neurol. Sci. 322, 141–147 (2012).
Snyder, H. M. et al. Vascular contributions to cognitive impairment and dementia including Alzheimer's disease. Alzheimers Dement. 11, 710–717 (2015).
Religa, P. et al. VEGF significantly restores impaired memory behavior in Alzheimer's mice by improvement of vascular survival. Sci. Rep. 3, 2053 (2013).
Patel, N. S. et al. Alzheimer's β-amyloid peptide blocks vascular endothelial growth factor mediated signaling via direct interaction with VEGFR-2. J. Neurochem. 112, 66–76 (2010).
Biron, K. E., Dickstein, D. L., Gopaul, R. & Jefferies, W. A. Amyloid triggers extensive cerebral angiogenesis causing blood brain barrier permeability and hypervascularity in Alzheimer's disease. PLoS ONE 6, e23789 (2011).
Zhang, Z., Cai, P., Zhou, J., Liu, M. & Jiang, X. Effects of asiaticoside on human umbilical vein endothelial cell apoptosis induced by Aβ1–42 . Int. J. Clin. Exp. Med. 8, 15828–15833 (2015).
Donnini, S. et al. Aβ peptides accelerate the senescence of endothelial cells in vitro and in vivo, impairing angiogenesis. FASEB J. 24, 2385–2395 (2010).
Solerte, S. B. et al. Decreased release of the angiogenic peptide vascular endothelial growth factor in Alzheimer's disease: recovering effect with insulin and DHEA sulfate. Dement. Geriatr. Cogn. Disord. 19, 1–10 (2005).
Mateo, I. et al. Low serum VEGF levels are associated with Alzheimer's disease. Acta Neurol. Scand. 116, 56–58 (2007).
Huang, L., Jia, J. & Liu, R. Decreased serum levels of the angiogenic factors VEGF and TGF-β1 in Alzheimer's disease and amnestic mild cognitive impairment. Neurosci. Lett. 550, 60–63 (2013).
Muche, A., Bigl, M., Arendt, T. & Schliebs, R. Expression of vascular endothelial growth factor (VEGF) mRNA, VEGF receptor 2 (Flk-1) mRNA, and of VEGF co-receptor neuropilin (Nrp)-1 mRNA in brain tissue of aging Tg2576 mice by in situ hybridization. Int. J. Dev. Neurosci. 43, 25–34 (2015).
Meyer, E. P., Ulmann-Schuler, A., Staufenbiel, M. & Krucker, T. Altered morphology and 3D architecture of brain vasculature in a mouse model for Alzheimer's disease. Proc. Natl Acad. Sci. USA 105, 3587–3592 (2008).
Dayalu, P. & Albin, R. L. Huntington disease: pathogenesis and treatment. Neurol. Clin. 33, 101–114 (2015).
Carroll, J. B., Bates, G. P., Steffan, J., Saft, C. & Tabrizi, S. J. Treating the whole body in Huntington's disease. Lancet Neurol. 14, 1135–1142 (2015).
Herrán, E. et al. VEGF-releasing biodegradable nanospheres administered by craniotomy: a novel therapeutic approach in the APP/Ps1 mouse model of Alzheimer's disease. J. Control. Release 170, 111–119 (2013).
Garcia, K. O. et al. Therapeutic effects of the transplantation of VEGF overexpressing bone marrow mesenchymal stem cells in the hippocampus of murine model of Alzheimer's disease. Front. Aging Neurosci. 6, 30 (2014).
Hohman, T. J., Bell, S. P. & Jefferson, A. L. The role of vascular endothelial growth factor in neurodegeneration and cognitive decline: exploring interactions with biomarkers of Alzheimer disease. JAMA Neurol. 72, 520–529 (2015).
Cesca, F. et al. Evaluating the SERCA2 and VEGF mRNAs as potential molecular biomarkers of the onset and progression in Huntington's disease. PLoS ONE 10, e0125259 (2015).
Emerich, D. F., Mooney, D. J., Storrie, H., Babu, R. S. & Kordower, J. H. Injectable hydrogels providing sustained delivery of vascular endothelial growth factor are neuroprotective in a rat model of Huntington's disease. Neurotox. Res. 17, 66–74 (2010).
Ellison, S. M. et al. Dose-dependent neuroprotection of VEGF165 in Huntington's disease striatum. Mol. Ther. 21, 1862–1875 (2013).
Aarli, J. A., Dua, T., Janca, A. & Muscetta, A. Neurological disorders. Public health challenges. World Health Organization http://www.who.int/mental_health/neurology/neurological_disorders_report_web.pdf (2006).
Wada, K. et al. Expression levels of vascular endothelial growth factor and its receptors in Parkinson's disease. Neuroreport 17, 705–709 (2006).
Cabezas, R. et al. Astrocytic modulation of blood brain barrier: perspectives on Parkinson's disease. Front. Cell. Neurosci. 8, 211 (2014).
Ohlin, K. E. et al. Vascular endothelial growth factor is upregulated by l-dopa in the parkinsonian brain: implications for the development of dyskinesia. Brain 134, 2339–2357 (2011).
Kortekaas, R. et al. Blood–brain barrier dysfunction in parkinsonian midbrain in vivo. Ann. Neurol. 57, 176–179 (2005).
Faucheux, B. A., Bonnet, A. M., Agid, Y. & Hirsch, E. C. Blood vessels change in the mesencephalon of patients with Parkinson's disease. Lancet 353, 981–982 (1999).
Issidorides, M. R. Neuronal vascular relationships in the zona compacta of normal and parkinsonian substantia nigra. Brain Res. 25, 289–299 (1971).
Guan, J. et al. Vascular degeneration in Parkinson's disease. Brain Pathol. 23, 154–164 (2013).
Rektor, I. et al. Impairment of brain vessels may contribute to mortality in patients with Parkinson's disease. Mov. Disord. 27, 1169–1172 (2012).
Tian, Y. Y. et al. Favorable effects of VEGF gene transfer on a rat model of Parkinson disease using adeno-associated viral vectors. Neurosci. Lett. 421, 239–244 (2007).
Yasuhara, T. et al. Neuroprotective effects of vascular endothelial growth factor (VEGF) upon dopaminergic neurons in a rat model of Parkinson's disease. Eur. J. Neurosci. 19, 1494–1504 (2004).
Yasuhara, T. et al. The differences between high and low-dose administration of VEGF to dopaminergic neurons of in vitro and in vivo Parkinson's disease model. Brain Res. 1038, 1–10 (2005).
Yasuhara, T. et al. Neurorescue effects of VEGF on a rat model of Parkinson's disease. Brain Res. 1053, 10–18 (2005).
Herran, E. et al. Increased antiparkinson efficacy of the combined administration of VEGF- and GDNF-loaded nanospheres in a partial lesion model of Parkinson's disease. Int. J. Nanomed. 9, 2677–2687 (2014).
Herran, E. et al. in vivo administration of VEGF- and GDNF-releasing biodegradable polymeric microspheres in a severe lesion model of Parkinson's disease. Eur. J. Pharm. Biopharm. 85, 1183–1190 (2013).
Requejo, C. et al. Topographical distribution of morphological changes in a partial model of Parkinson's disease — effects of nanoencapsulated neurotrophic factors administration. Mol. Neurobiol. 52, 846–858 (2015).
Glavaski-Joksimovic, A. & Bohn, M. C. Mesenchymal stem cells and neuroregeneration in Parkinson's disease. Exp. Neurol. 247, 25–38 (2013).
Xiong, N. et al. VEGF-expressing human umbilical cord mesenchymal stem cells, an improved therapy strategy for Parkinson's disease. Gene Ther. 18, 394–402 (2011).
Yue, X. et al. Comparative study of the neurotrophic effects elicited by VEGF-B and GDNF in preclinical in vivo models of Parkinson's disease. Neuroscience 258, 385–400 (2014).
Falk, T., Zhang, S. & Sherman, S. J. Vascular endothelial growth factor B (VEGF-B) is up-regulated and exogenous VEGF-B is neuroprotective in a culture model of Parkinson's disease. Mol. Neurodegener. 4, 49 (2009).
Falk, T. et al. Vascular endothelial growth factor-B is neuroprotective in an in vivo rat model of Parkinson's disease. Neurosci. Lett. 496, 43–47 (2011).
Pienaar, I. S. et al. Deep-brain stimulation associates with improved microvascular integrity in the subthalamic nucleus in Parkinson's disease. Neurobiol. Dis. 74, 392–405 (2015).
Remple, M. S. et al. Subthalamic nucleus neuronal firing rate increases with Parkinson's disease progression. Mov. Disord. 26, 1657–1662 (2011).
Shinko, A. et al. Spinal cord stimulation exerts neuroprotective effects against experimental Parkinson's disease. PLoS ONE 9, e101468 (2014).
Sytze Van Dam, P., Cotter, M. A., Bravenboer, B. & Cameron, N. E. Pathogenesis of diabetic neuropathy: focus on neurovascular mechanisms. Eur. J. Pharmacol. 719, 180–186 (2013).
Carozzi, V. A., Canta, A. & Chiorazzi, A. Chemotherapy-induced peripheral neuropathy: what do we know about mechanisms? Neurosci. Lett. 596, 90–107 (2015).
Giannini, C. & Dyck, P. J. Basement membrane reduplication and pericyte degeneration precede development of diabetic polyneuropathy and are associated with its severity. Ann. Neurol. 37, 498–504 (1995).
Shimizu, F., Sano, Y., Haruki, H. & Kanda, T. Advanced glycation end-products induce basement membrane hypertrophy in endoneurial microvessels and disrupt the blood–nerve barrier by stimulating the release of TGF-β and vascular endothelial growth factor (VEGF) by pericytes. Diabetologia 54, 1517–1526 (2011).
Dyck, P. J. & Giannini, C. Pathologic alterations in the diabetic neuropathies of humans: a review. J. Neuropathol. Exp. Neurol. 55, 1181–1193 (1996).
Schratzberger, P. et al. Reversal of experimental diabetic neuropathy by VEGF gene transfer. J. Clin. Invest. 107, 1083–1092 (2001).
Kirchmair, R. et al. Therapeutic angiogenesis inhibits or rescues chemotherapy-induced peripheral neuropathy: taxol- and thalidomide-induced injury of vasa nervorum is ameliorated by VEGF. Mol. Ther. 15, 69–75 (2007).
Kirchmair, R. et al. Antiangiogenesis mediates cisplatin-induced peripheral neuropathy: attenuation or reversal by local vascular endothelial growth factor gene therapy without augmenting tumor growth. Circulation 111, 2662–2670 (2005).
Samii, A., Unger, J. & Lange, W. Vascular endothelial growth factor expression in peripheral nerves and dorsal root ganglia in diabetic neuropathy in rats. Neurosci. Lett. 262, 159–162 (1999).
Peng, L., Liu, W., Zhai, F., He, L. & Wang, H. Microvessel permeability correlates with diabetic peripheral neuropathy in early stage of streptozotocin-induced diabetes rats. J. Diabetes Complications 29, 865–871 (2015).
Taiana, M. M. et al. Neutralization of Schwann cell-secreted VEGF is protective to in vitro and in vivo experimental diabetic neuropathy. PLoS ONE 9, e108403 (2014).
Schratzberger, P. et al. Favorable effect of VEGF gene transfer on ischemic peripheral neuropathy. Nat. Med. 6, 405–413 (2000).
Verheyen, A. et al. Systemic anti-vascular endothelial growth factor therapies induce a painful sensory neuropathy. Brain 135, 2629–2641 (2012).
Verheyen, A. et al. Therapeutic potential of VEGF and VEGF-derived peptide in peripheral neuropathies. Neuroscience 244, 77–89 (2013).
Bates, D. O. et al. VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. Cancer Res. 62, 4123–4131 (2002).
Woolard, J. et al. VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action. in vivo effect on angiogenesis and endogenous protein expression. Cancer Res. 64, 7822–7835 (2004).
Beazley-Long, N. et al. VEGF-A165b is an endogenous neuroprotective splice isoform of vascular endothelial growth factor A in vivo and in vitro. Am J. Pathol. 183, 918–929 (2013).
Hulse, R. P. et al. Vascular endothelial growth factor-A165b prevents diabetic neuropathic pain and sensory neuronal degeneration. Clin. Sci. (Lond.) 129, 741–756 (2015).
Dhondt, J. et al. Neuronal FLT1 receptor and its selective ligand VEGF-B protect against retrograde degeneration of sensory neurons. FASEB J. 25, 1461–1473 (2011).
Selvaraj, D. et al. A functional role for VEGFR1 expressed in peripheral sensory neurons in cancer pain. Cancer Cell 27, 780–796 (2015).
Simovic, D., Isner, J. M., Ropper, A. H., Pieczek, A. & Weinberg, D. H. Improvement in chronic ischemic neuropathy after intramuscular phVEGF165 gene transfer in patients with critical limb ischemia. Arch. Neurol. 58, 761–768 (2001).
Ropper, A. H. et al. Vascular endothelial growth factor gene transfer for diabetic polyneuropathy: a randomized, double-blinded trial. Ann. Neurol. 65, 386–393 (2009).
Ma, Y., Zechariah, A., Qu, Y. & Hermann, D. M. Effects of vascular endothelial growth factor in ischemic stroke. J. Neurosci. Res. 90, 1873–1882 (2012).
Zhang, Z. G. et al. VEGF enhances angiogenesis and promotes blood–brain barrier leakage in the ischemic brain. J. Clin. Invest. 106, 829–838 (2000).
van Bruggen, N. et al. VEGF antagonism reduces edema formation and tissue damage after ischemia/reperfusion injury in the mouse brain. J. Clin. Invest. 104, 1613–1620 (1999).
Lu, K. T. et al. Hippocampal neurogenesis after traumatic brain injury is mediated by vascular endothelial growth factor receptor-2 and the Raf/MEK/ERK cascade. J. Neurotrauma 28, 441–450 (2011).
Marti, H. J. et al. Hypoxia-induced vascular endothelial growth factor expression precedes neovascularization after cerebral ischemia. Am. J. Pathol. 156, 965–976 (2000).
Baumann, G., Travieso, L., Liebl, D. J. & Theus, M. H. Pronounced hypoxia in the subventricular zone following traumatic brain injury and the neural stem/progenitor cell response. Exp. Biol. Med. 238, 830–841 (2013).
Thored, P. et al. Long-term neuroblast migration along blood vessels in an area with transient angiogenesis and increased vascularization after stroke. Stroke 38, 3032–3039 (2007).
Mellergård, P., Sjögren, F. & Hillman, J. Release of VEGF and FGF in the extracellular space following severe subarachnoidal haemorrhage or traumatic head injury in humans. Br. J. Neurosurg. 24, 261–267 (2010).
Slevin, M. et al. Serial measurement of vascular endothelial growth factor and transforming growth factor-β1 in serum of patients with acute ischemic stroke. Stroke 31, 1863–1870 (2000).
Pikula, A. et al. Serum brain-derived neurotrophic factor and vascular endothelial growth factor levels are associated with risk of stroke and vascular brain injury: Framingham Study. Stroke 44, 2768–2775 (2013).
Lapilover, E. G. et al. Peri-infarct blood–brain barrier dysfunction facilitates induction of spreading depolarization associated with epileptiform discharges. Neurobiol. Dis. 48, 495–506 (2012).
Terpolilli, N. A. et al. Inhalation of nitric oxide prevents ischemic brain damage in experimental stroke by selective dilatation of collateral arterioles. Circ. Res. 110, 727–738 (2012).
Moisan, A. et al. Microvascular plasticity after experimental stroke: a molecular and MRI study. Cerebrovasc. Dis. 38, 344–353 (2014).
Greenberg, D. A. & Jin, K. Vascular endothelial growth factors (VEGFs) and stroke. Cell. Mol. Life Sci. 70, 1753–1761 (2013).
Svensson, B. et al. Vascular endothelial growth factor protects cultured rat hippocampal neurons against hypoxic injury via an antiexcitotoxic, caspase-independent mechanism. J. Cereb. Blood Flow Metab. 22, 1170–1175 (2002).
Thau-Zuchman, O., Shohami, E., Alexandrovich, A. G. & Leker, R. R. Vascular endothelial growth factor increases neurogenesis after traumatic brain injury. J. Cereb. Blood Flow Metab. 30, 1008–1016 (2010).
Tado, M. et al. Increased expression of vascular endothelial growth factor attenuates contusion necrosis without influencing contusion edema after traumatic brain injury in rats. J. Neurotrauma 31, 691–698 (2014).
Gaal, E. I. et al. Comparison of vascular growth factors in the murine brain reveals placenta growth factor as prime candidate for CNS revascularization. Blood 122, 658–665 (2013).
Siddiq, I. et al. Treatment of traumatic brain injury using zinc-finger protein gene therapy targeting VEGF-A. J. Neurotrauma 29, 2647–2659 (2012).
D'Andrea, L. D. et al. Targeting angiogenesis: structural characterization and biological properties of a de novo engineered VEGF mimicking peptide. Proc. Natl Acad. Sci. USA 102, 14215–14220 (2005).
Pignataro, G. et al. Neuroprotective effect of VEGF-mimetic peptide QK in experimental brain ischemia induced in rat by middle cerebral artery occlusion. ACS Chem. Neurosci. 6, 1517–1525 (2015).
Maxwell, P. H. & Eckardt, K. U. HIF prolyl hydroxylase inhibitors for the treatment of renal anaemia and beyond. Nat. Rev. Nephrol. 12, 157–168 (2016).
Kunze, R. et al. Neuron-specific prolyl-4-hydroxylase domain 2 knockout reduces brain injury after transient cerebral ischemia. Stroke 43, 2748–2756 (2012).
Reischl, S. et al. Inhibition of HIF prolyl-4-hydroxylases by FG-4497 reduces brain tissue injury and edema formation during ischemic stroke. PLoS ONE 9, e84767 (2014).
Ogle, M. E., Gu, X., Espinera, A. R. & Wei, L. Inhibition of prolyl hydroxylases by dimethyloxaloylglycine after stroke reduces ischemic brain injury and requires hypoxia inducible factor-1α. Neurobiol. Dis. 45, 733–742 (2012).
Bernaudin, M. et al. Normobaric hypoxia induces tolerance to focal permanent cerebral ischemia in association with an increased expression of hypoxia-inducible factor-1 and its target genes, erythropoietin and VEGF, in the adult mouse brain. J. Cereb. Blood Flow Metab. 22, 393–403 (2002).
Quaegebeur, A. et al. Deletion or inhibition of the oxygen sensor PHD1 protects against ischemic stroke via reprogramming of neuronal metabolism. Cell Metab. 23, 280–291 (2016).
Segura, I. et al. The oxygen sensor PHD2 controls dendritic spines and synapses via modification of filamin A. Cell Rep. 14, 2653–2667 (2016).
Zhang, J. & Chopp, M. Cell-based therapy for ischemic stroke. Expert Opin. Biol. Ther. 13, 1229–1240 (2013).
Wang, J. et al. Preconditioning with VEGF enhances angiogenic and neuroprotective effects of bone marrow mononuclear cell transplantation in a rat model of chronic cerebral hypoperfusion. Mol. Neurobiol. http://dx.doi.org/10.1007/s12035-015-9512-8 (2015).
Rigau, V. et al. Angiogenesis is associated with blood–brain barrier permeability in temporal lobe epilepsy. Brain 130, 1942–1956 (2007).
Croll, S. D., Goodman, J. H. & Scharfman, H. E. Vascular endothelial growth factor (VEGF) in seizures: a double-edged sword. Adv. Exp. Med. Biol. 548, 57–68 (2004).
van Vliet, E. A. et al. Blood–brain barrier leakage may lead to progression of temporal lobe epilepsy. Brain 130, 521–534 (2007).
Tomkins, O. et al. Blood–brain barrier disruption results in delayed functional and structural alterations in the rat neocortex. Neurobiol. Dis. 25, 367–377 (2007).
Obermeier, B., Daneman, R. & Ransohoff, R. M. Development, maintenance and disruption of the blood–brain barrier. Nat. Med. 19, 1584–1596 (2013).
Morin-Brureau, M. et al. Epileptiform activity induces vascular remodeling and zonula occludens 1 downregulation in organotypic hippocampal cultures: role of VEGF signaling pathways. J. Neurosci. 31, 10677–10688 (2011).
Nicoletti, J. N. et al. Vascular endothelial growth factor attenuates status epilepticus-induced behavioral impairments in rats. Epilepsy Behav. 19, 272–277 (2010).
Nicoletti, J. N. et al. Vascular endothelial growth factor is up-regulated after status epilepticus and protects against seizure-induced neuronal loss in hippocampus. Neuroscience 151, 232–241 (2008).
Nikitidou, L. et al. VEGF receptor-2 (Flk-1) overexpression in mice counteracts focal epileptic seizures. PLoS ONE 7, e40535 (2012).
Tomizawa, Y. et al. Blood–brain barrier disruption is more severe in neuromyelitis optica than in multiple sclerosis and correlates with clinical disability. J. Int. Med. Res. 40, 1483–1491 (2012).
Minagar, A. & Alexander, J. S. Blood–brain barrier disruption in multiple sclerosis. Mult. Scler. 9, 540–549 (2003).
Su, J. J. et al. Upregulation of vascular growth factors in multiple sclerosis: correlation with MRI findings. J. Neurol. Sci. 243, 21–30 (2006).
Shimizu, F. et al. Sera from neuromyelitis optica patients disrupt the blood–brain barrier. J. Neurol. Neurosurg. Psychiatry 83, 288–297 (2012).
Proescholdt, M. A., Jacobson, S., Tresser, N., Oldfield, E. H. & Merrill, M. J. Vascular endothelial growth factor is expressed in multiple sclerosis plaques and can induce inflammatory lesions in experimental allergic encephalomyelitis rats. J. Neuropathol. Exp. Neurol. 61, 914–925 (2002).
Argaw, A. T. et al. IL-1β regulates blood–brain barrier permeability via reactivation of the hypoxia–angiogenesis program. J. Immunol. 177, 5574–5584 (2006).
Argaw, A. T. et al. Astrocyte-derived VEGF-A drives blood–brain barrier disruption in CNS inflammatory disease. J. Clin. Invest. 122, 2454–2468 (2012).
MacMillan, C. J. et al. Bevacizumab diminishes experimental autoimmune encephalomyelitis by inhibiting spinal cord angiogenesis and reducing peripheral T-cell responses. J. Neuropathol. Exp. Neurol. 71, 983–999 (2012).
Mantel, I. Optimizing the anti-VEGF treatment strategy for neovascular age-related macular degeneration: from clinical trials to real-life requirements. Transl. Vis. Sci. Technol. 4, 6 (2015).
Baker, C. W., Jiang, Y. & Stone, T. Recent advancements in diabetic retinopathy from the Diabetic Neuropathy Clinical Research Network. Curr. Opin. Ophthalmol. 27, 210–216 (2016).
Jin, K., Wang, X., Xie, L., Mao, X. O. & Greenberg, D. A. Transgenic ablation of doublecortin-expressing cells suppresses adult neurogenesis and worsens stroke outcome in mice. Proc. Natl Acad. Sci. USA 107, 7993–7998 (2010).
Blaiss, C. A. et al. Temporally specified genetic ablation of neurogenesis impairs cognitive recovery after traumatic brain injury. J. Neurosci. 31, 4906–4916 (2011).
Kirby, E. D., Kuwahara, A. A., Messer, R. L. & Wyss-Coray, T. Adult hippocampal neural stem and progenitor cells regulate the neurogenic niche by secreting VEGF. Proc. Natl Acad. Sci. USA 112, 4128–4133 (2015).
Cao, L. et al. VEGF links hippocampal activity with neurogenesis, learning and memory. Nat. Genet. 36, 827–835 (2004).
Jin, K. et al. Vascular endothelial growth factor (VEGF) stimulates neurogenesis in vitro and in vivo. Proc Natl Acad. Sci. USA 99, 11946–11950 (2002).
Fabel, K. et al. VEGF is necessary for exercise-induced adult hippocampal neurogenesis. Eur. J. Neurosci. 18, 2803–2812 (2003).
Sun, Y. et al. VEGF-induced neuroprotection, neurogenesis, and angiogenesis after focal cerebral ischemia. J. Clin. Invest. 111, 1843–1851 (2003).
Lee, C. & Agoston, D. V. Inhibition of VEGF receptor 2 increased cell death of dentate hilar neurons after traumatic brain injury. Exp. Neurol. 220, 400–403 (2009).
Licht, T. et al. Reversible modulations of neuronal plasticity by VEGF. Proc. Natl Acad. Sci. USA 108, 5081–5086 (2011).
Cattin, A. L. et al. Macrophage-induced blood vessels guide Schwann cell-mediated regeneration of peripheral nerves. Cell 162, 1127–1139 (2015).
Cho, Y. et al. Activating injury-responsive genes with hypoxia enhances axon regeneration through neuronal HIF-1α. Neuron 88, 720–734 (2015).
Ambati, J. & Fowler, B. J. Mechanisms of age-related macular degeneration. Neuron 75, 26–39 (2012).
Miller, J. W., Adamis, A. P. & Aiello, L. P. Vascular endothelial growth factor in ocular neovascularization and proliferative diabetic retinopathy. Diabetes Metab. Rev. 13, 37–50 (1997).
Lai, C. M. et al. Generation of transgenic mice with mild and severe retinal neovascularisation. Br. J. Ophthalmol. 89, 911–916 (2005).
Shen, W. Y. et al. Long-term global retinal microvascular changes in a transgenic vascular endothelial growth factor mouse model. Diabetologia 49, 1690–1701 (2006).
van Eeden, P. E. et al. Early vascular and neuronal changes in a VEGF transgenic mouse model of retinal neovascularization. Invest. Ophthalmol. Vis. Sci. 47, 4638–4645 (2006).
Wang, F. et al. AAV-mediated expression of vascular endothelial growth factor induces choroidal neovascularization in rat. Invest. Ophthalmol. Vis. Sci. 44, 781–790 (2003).
Huang, H. et al. Deletion of placental growth factor prevents diabetic retinopathy and is associated with Akt activation and HIF1α–VEGF pathway inhibition. Diabetes 64, 200–212 (2015).
Lazzeri, S. et al. Aflibercept administration in neovascular age-related macular degeneration refractory to previous anti-vascular endothelial growth factor drugs: a critical review and new possible approaches to move forward. Angiogenesis 18, 397–432 (2015).
Van de Veire, S. et al. Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease. Cell 141, 178–190 (2010).
Rakic, J. M. et al. Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 44, 3186–3193 (2003).
Nishijima, K. et al. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am. J. Pathol. 171, 53–67 (2007).
Foxton, R. H. et al. VEGF-A is necessary and sufficient for retinal neuroprotection in models of experimental glaucoma. Am. J. Pathol. 182, 1379–1390 (2013).
Park, H. Y., Kim, J. H. & Park, C. K. Neuronal cell death in the inner retina and the influence of vascular endothelial growth factor inhibition in a diabetic rat model. Am. J. Pathol. 184, 1752–1762 (2014).
Acknowledgements
C.L. is a postdoctoral fellow of the Fonds Wetenschappelijk Onderzoek (FWO). E.S. is supported by funding from the Max Planck Society, the state of North Rhine-Westphalia, the Frick Foundation for ALS Research, the Minna James Heineman Foundation and the French Muscular Dystrophy Association (AFM). C.R.d.A. is supported by grants ERC-StG-311367, FP7-PEOPLE-2011-CIG-304054 and DFG-FOR 2325, and the Schram Foundation. M.D. is supported by the Belgian Science Policy (grants IAP-P6/20 and IAP-P7/20). P.C. is supported by the Belgian Science Policy (grant IAP-P7/03), long-term structural Methusalem funding from the Flemish Government, grants from the FWO (G.0595.12N, 1.5.149.13N and 1.5.211.14N), the Foundation Leducq Transatlantic Network (ARTEMIS), the 'A cure for ALS' fund from the ALS League Belgium, the Motor Neuron Disease Association, the ALS Association (ID#C44128), Euro-MOTOR (EU HEALTH project), and the Leuven University Fund — Opening the Future.
Author information
Authors and Affiliations
Contributions
All authors researched data for the article, made substantial contributions to discussions of the content, wrote the article, and reviewed and/or edited the manuscript before submission.
Corresponding author
Ethics declarations
Competing interests
P.C. is named as inventor on patent applications WO 01/76620 and WO 2005/117946 and applicable resulting patents, which relate to results described in this article. The aforementioned patent application has been licensed, which may result in a royalty payment to P.C. The other authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Lange, C., Storkebaum, E., de Almodóvar, C. et al. Vascular endothelial growth factor: a neurovascular target in neurological diseases. Nat Rev Neurol 12, 439–454 (2016). https://doi.org/10.1038/nrneurol.2016.88
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneurol.2016.88
This article is cited by
-
Blockage of VEGF function by bevacizumab alleviates early-stage cerebrovascular dysfunction and improves cognitive function in a mouse model of Alzheimer’s disease
Translational Neurodegeneration (2024)
-
Egr-1 is a key regulator of the blood-brain barrier damage induced by meningitic Escherichia coli
Cell Communication and Signaling (2024)
-
Pathophysiology and probable etiology of cerebral small vessel disease in vascular dementia and Alzheimer’s disease
Molecular Neurodegeneration (2023)
-
Infection of the murine placenta by Listeria monocytogenes induces sex-specific responses in the fetal brain
Pediatric Research (2023)
-
Modeling angiogenesis in the human brain in a tissue-engineered post-capillary venule
Angiogenesis (2023)